AbCellera Biologics Inc. ABCL Licensing and royalty revenue — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s licensing and royalty revenue — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s licensing and royalty revenue — total revenue?
- AbCellera Biologics Inc. (ABCL) reported licensing and royalty revenue — total revenue of $191K in Q1 2026.
- What does licensing and royalty revenue — total revenue mean?
- This metric represents the total gross revenue generated from licensing intellectual property and royalty payments derived from commercialized products developed through the company's technology platform. It serves as a key indicator of the successful monetization of the company's research and development efforts and the commercial adoption of its partnered assets. Growth in this area reflects the company's ability to transition from early-stage discovery services to long-term, recurring revenue streams.